Key Highlights
- Dr. Sandeep Athalye appointed as Global CEO of Kashiv BioSciences.
- Over 20 years of experience in top pharmaceutical firms.
- Will drive strategic growth across U.S., Europe, and Asia.
- Known for patient-centric and innovative strategies.
- Focused on expanding biosimilars pipeline and global reach.
Source: Business Wire
Notable Quotes
- “We are delighted to welcome Dr. Athalye to Kashiv. His appointment comes at a pivotal time as we accelerate our growth in the rapidly expanding biosimilars sector. We are confident that Dr. Athalye’s industry expertise and leadership will be instrumental in achieving Kashiv’s ambitious global vision.” — Chirag and Chintu Patel, Co-Founders and Board Members at Kashiv BioSciences, LLC
- “Kashiv is an ambitious biosimilars company founded with a vision to bring affordable and accessible biosimilars globally. I am very excited for the opportunity to use technology and innovation to drive Kashiv to become one of the leading developers of medicines in the biologics space.” — Dr. Sandeep Nilkanth Athalye, Global CEO at Kashiv BioSciences, LLC
SoHC's Take
The appointment of Dr. Sandeep Athalye as Global CEO signals Kashiv BioSciences’ commitment to scaling its impact in the biosimilars market, a sector with growing global demand for accessible biologics. Dr. Athalye’s impressive portfolio in regulatory strategy, clinical development, and leadership in established biopharma firms positions him as a catalyst for Kashiv’s ambitious expansion. His focus on patient-centric innovation aligns well with Kashiv’s vision, promising new advancements in affordability and accessibility in biosimilar solutions across multiple continents. This leadership change underscores Kashiv’s readiness to leverage technological advances and robust R&D infrastructure to solidify its standing in the competitive biosimilars landscape.
